Condition: Diffuse Large B Cell Lymphoma · Solid Tumor Cancer · Sponsor: OWKIN
Cancer is amongst the leading causes of disease-related morbidity and mortality. A major challenge in cancer treatment is the development of biology-informed, personalised treatment strategies. Recent advances in artificial intelligence (AI) and next-generation sequencing (NGS) technologies have shed further insights into disease biology and treatment pathways, thus identifying new, precision medicine-based therapeutic opportunities. The biological mechanisms leading to cancer development and progression arise from complex and plastic networks of dysregulated cellular programs involving many signalling pathways and effector molecules. Cancer cells alter their surrounding environment via cell-cell interactions with non-tumor cells or by secreting cytokines, chemokines and other factors. This reprogramming of the tumour microenvironment (TME) is critical for cancer progression, invasion, and metastasis. Moreover, there are increasing studies that show that both innate and adaptive immune cell types contribute to tumorigenesis and treatment resistance when present within the TME. Understanding the crosstalk between cancer cells and the surrounding TME will inform on mechanisms of sensitivity and resistance to treatment, including immunotherapy (IO) and targeted therapies. Spatially resolved-Omics is an emerging field that characterises cell types by gene/protein expressions within their spatial context in the tissue organisation. Recent high profile spatial transcriptomics stu…
This description comes directly from the study's public registry record.
Hubert Chaperon · +33 6 45 63 71 12 · hubert.chaperon@owkin.com
Ginevra Ferrarini · ginevra.ferrarini@owkin.com
Always discuss trial participation with your own doctor first.
| University of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| Gustave Roussy | Paris, France | Recruiting |
| Charité - Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| Universiy Hospital Erlangen & FAU Erlangen-Nürnberg | Erlangen, Germany | Recruiting |
| Centre Hospitalier Universitaire Vaudois | Lausanne, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06625203